Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Reports Q2 revenue EUR 1.34M vs. EUR 771,000 last year. “This FDA approval represents a historic milestone for Nyxoah (NYXH) and marks the ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

Analysts estimate that Nyxoah will report an earnings per share (EPS) of $-0.63. Nyxoah bulls will hope to hear the company ...

Nyxoah SA (NASDAQ:NYXH) is set to release its Q2 2025 earnings on Aug 18, 2025. The consensus estimate for Q2 2025 revenue is ...

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Monday, March 17, 2025, at 8:40am ET. A webcast of the presentation will be available in the Events ...

Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.02 million.